LI
OCUL icon

Leap Investments’s Ocular Therapeutix OCUL Stock Holding History

Leap Investments’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$112K Buy
+13,500
New +$89.5K 0.07% 349

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Leap Investments's OCUL Position: Q2 2020 in Review

Leap Investments opened a new position in Ocular Therapeutix (OCUL) in Q2 2020: 13,500 shares worth $112K. The stake represents 0.07% of the portfolio and ranks #349 among its holdings.

106 funds tracked by Wall St. Rank hold OCUL as of Q2 2020.

  • Leap Investments held 13,500 shares of Ocular Therapeutix worth $112K as of Q2 2020.
  • Ocular Therapeutix was a new Leap Investments position in Q2 2020.
  • Ocular Therapeutix made up 0.07% of Leap Investments's portfolio in Q2 2020, its #349 holding.
  • 106 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.